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Switching off signals
in hematopoietic cells, the protein tyrosine phosphatase PTP1 C
appears to play a central role in the termination of signalling
by receptors that activate protein tyrosine kinases.
Receptors for a wide range of growth factors and cyto-
kines, as well as the antigen receptors expressed by
lymphocytes, mediate their effects on cells through the
activation of protein tyrosine kinases. Receptor-activated
protein tyrosine kinases transduce signals by phosphory-
lating the receptor itself, which in turn recruits signalling
molecules to the receptor, and by phosphorylating (and
thereby functionally modifying) key components of
signalling cascades. While there has been remarkable
progress in understanding the initiation of signal transduc-
tion by protein-tyrosine-kinase-coupled receptors, until
recently there has been little insight into how cells termi-
nate signalling by these receptors. The central role played
by tyrosine phosphorylation suggests that protein tyrosine
phosphatases might switch off signals by dephosphory-
lating critical molecules. A combination of genetic and
biochemical approaches now indicates that, at least in the
case of hematopoietic cells, this is indeed the case, and
points to a critical role for protein tyrosine phosphatases
in the termination of receptor signaling.
Interestingly, the initial studies of protein tyrosine phos-
phatases in hematopoietic cells established a positive role
for a protein tyrosine phosphatase in the regulation of
signalling by receptor-activated protein tyrosine kinases.
CD45, a highly expressed, hematopoietic-cell-specific
transmembrane molecule, was the first protein tyrosine
phosphatase identified in lymphoid cells [1]. At first it
was assumed that CD45 would function to inhibit
lymphocyte activation by acting as a counterpart to the
protein tyrosine kinases that are activated following stim-
ulation of the antigen receptors expressed by these cells.
It was surprising, therefore, when Pingel and Thomas [2]
demonstrated that stimulation of the antigen receptor on
a CD45-deficient murine T-cell line failed to result in
cellular activation. Subsequent studies from a number of
laboratories extended these observations to B cells and
natural killer cells, and established that the early signalling
events associated with receptor ligation fail to occur in
the absence of CD45.
An attractive model to explain these observations proposes
that the most proximal protein tyrosine kinase activated by
receptor ligation is a substrate for CD45 and requires
dephosphorylation for activation. Protein tyrosine kinases
of the Src family appear to initiate antigen receptor sig-
naling. The enzymatic activity of these Src-like protein
tyrosine kinases is inhibited by phosphorylation of a
carboxy-terminal tyrosine, and CD45 can dephosphorylate
this regulatory tyrosine [3]. Thus, the apparent paradox of
the requirement for CD45 for the initiation of receptor-
mediated signals may be explained by a CD45-dependent
dephosphorylation event that is necessary for the activation
of a receptor-associated protein tyrosine kinase.
CD45 is not the only protein tyrosine phosphatase that
plays an essential, positive role in signal transduction. Syp
(also known as PTP1D, SH-PTP2 and PTP2C) is a
ubiquitously expressed, cytosolic protein tyrosine phos-
phatase which contains two Src homology 2 (SH2)
domains. These domains, which are found in a number
of different signaling molecules, recognize certain
tyrosine-phosphorylated sequences. Indeed, Syp binds to
tyrosine-phosphorylated growth factor receptors by
means of its SH2 domains and appears to act as an adap-
tor molecule, enhancing the ability of growth factor
receptors to couple to their downstream signaling path-
ways [4]. Similarly, a homologous protein tyrosine phos-
phatase isolated from Drosophila (the corkscrew gene
product) appears to play a positive role in protein-
tyrosine-kinase-mediated signaling [5].
In contrast to the positive roles played by CD45 and Syp,
it now appears that other protein tyrosine phosphatases
can switch off signalling events. The best such example
comes from studies of PTP1C (also known as HCP, SHP
and SH-PTP1), a cytosolic protein tyrosine phosphatase
which is expressed exclusively by hematopoietic cells
and which, like Syp, contains two SH2 domains. In a
recently published series of elegant experiments, Kling-
muller et al. [6] demonstrate that PTP1C terminates
proliferative signals delivered by the receptor for erythro-
poietin (EPO), a growth factor that supports the prolifer-
ation and differentiation of the erythroid line.
Like other type I cytokine receptors, the EPO receptor
lacks intrinsic protein tyrosine kinase activity. Critical for
EPO receptor signalling is its interaction with a non-
receptor protein tyrosine kinase, Janus kinase 2 AK2).
The addition of EPO triggers the tyrosine phosphory-
lation and activation of JAK2, as well as the tyrosine
phosphorylation of the EPO receptor itself [7]. As
Klingmuller et al. [6] demonstrate, EPO also induces an
association between the EPO receptor and PTP1C.
Phosphorylation of residue Tyr429 in the EPO receptor
apparently creates a binding site for the SH2 domains of
PTP1C, permitting the recruitment of the protein tyro-
sine phosphatase to the receptor. Thus, substituting
Tyr429 with phenylalanine prevents the EPO-induced
association between the receptor and PTP1C, and fusion
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proteins containing the SH2 domains of PTP1C bind
wild-type receptors, but not Phe429 mutants, from
EPO-stimulated cells [6].
The tyrosine phosphorylation of JAK2 following the
addition of EPO is a transient event. In 32D cells
expressing wild-type EPO receptors and exposed to
EPO, for example, phosphorylation of JAK2 peaks at
5 minutes, and returns to basal levels after 45 minutes [6].
In marked contrast, when EPO is added to 32D cells
expressing mutant EPO receptors unable to bind
PTP1C, phosphorylation of JAK2 persists at high levels
for more than 60 minutes [6]. The cells expressing the
mutant receptors remain dependent upon EPO for
growth but achieve maximal proliferative responses in
the presence of one-tenth the concentration of EPO
normally required [6]. These results suggest that EPO-
induced oligomerization of its receptor not only initiates
signal transduction but also, by inducing phosphoryla-
tion of receptor residue Tyr429, programs the termina-
tion of signalling (Fig. 1). Phosphorylation of this site
recruits PTP1C to the receptor, where it appears to
dephosphorylate (and presumably inactivate) JAK2,
thereby switching off the proliferative signal.
An impaired ability to terminate EPO signals may
explain a form of benign erythrocytosis in humans. In
one well-studied Finnish family, erythrocytosis (mani-
fested by a high hemoglobin level and hematocrit) is
inherited in an autosomal dominant fashion [8]. This
trait stems from a mutation in one allele of the EPO
receptor gene, resulting in a premature stop codon and a
truncated EPO receptor [8]. As Klingmuller and col-
leagues point out [6], the truncated receptor lacks the
Fig. 1. Model for the termination of EPO signals by the protein
tyrosine phosphatase PTP1C. EPO triggers dimerization of its
receptor, leading to the tyrosine phosphorylation and activation
of JAK2, a receptor-associated protein tyrosine kinase that trans-
duces a proliferative signal. Receptor dimerization also triggers
the phosphorylation of Tyr429 of the receptor itself. Phosphory-
lation of this residue, which creates a recognition site for the
SH2 domains of PTP1C, recruits PTP1C to the EPO receptor
where it dephosphorylates JAK2, terminating the EPO-induced
proliferative signal. (Adapted from [6].)
binding site for PTP1C and thus should display enhanced
sensitivity to EPO. Interestingly, expression of one
mutant allele (all individuals studied have been hetero-
zygotes) has no apparent adverse clinical manifestations.
Indeed, by increasing oxygen transport capacity, the trait
may have conferred a competitive advantage upon one
proband, who was a world champion cross-country skier
and a three-time Olympic gold medalist [8].
PTP1C appears to play an important role in the negative
regulation of a variety of signals in hematopoietic cells.
Mutations in the gene encoding murine PTP1C are
responsible for the phenotype known as motheaten [9].
Mice homozygous for these mutations fail to express a
functional PTP1C and display severe developmental
abnormalities involving all hematopoietic lines [9]. In
view of these extensive hematological abnormalities, it is
likely that the paradigm presented by the EPO receptor
can be extended to receptors for multiple other
hematopoietic growth factors and cytokines. PTP1C is
known already to associate with the receptor tyrosine
kinase c-Kit, and with the receptors for colony stimulat-
ing factor-1 (CSF-1) and interleukin-3, raising the possi-
bility that PTP1C might terminate signals from these
receptors [9,10]. Hypersensitivity to CSF-1, it has been
postulated, may explain the striking accumulation of
macrophages that occurs in motheaten mice [9]. Recent
studies of B cells from motheaten mice, moreover, impli-
cate PTP1C in the negative regulation of B-cell antigen
receptor signalling [11].
PTP1C also appears to be involved in an important
example of 'cross-talk' between two receptor types.
Immune complexes composed of immunoglobulin G and
antigen are potent inhibitors of B cells specific for the
antigen, and down-regulate humoral immune responses.
This inhibition requires simultaneous ligation of two dif-
ferent receptors by the immune complex: the B-cell anti-
gen receptor (bound by the antigen component of the
immune complex) and the receptor for the Fc region of
immunoglobulin G (FcyRIIB1). Co-ligation of the B-
cell antigen receptor with FcyRIIB1 abrogates B-cell
activation by blocking signal transduction through the
B-cell antigen receptor.
In a recent publication, D'Ambrosio and colleagues [12]
implicate PTP1C as the mediator used by FcyRIIB1 to
turn offB-cell antigen receptor signalling. Co-ligation of
the B-cell antigen receptor with FcyRIIB1 induces tyro-
sine phosphorylation of a sequence within the FcyRIIB1
cytoplasmic domain that is required for the inhibition of
the B-cell antigen receptor. D'Ambrosio et al. [12] find that
this phosphorylation forms a recognition site for the SH2
domains of PTP1C and leads to the recruitment of PTP1C
to FcyRIIB1 [12]. Interestingly, a peptide corresponding
to the phosphorylated FcyRIIB1 sequence both binds
PTP1C and increases its enzymatic activity, raising the
possibility that SH2 domain-based recruitment of PTP1C
to FcyRIIB1 (and perhaps to other receptors as well)
results in the activation of its phosphatase activity [12].
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The ability to recruit and activate PTP1C appears to be
critical for the inhibition of B-cell antigen receptor sig-
naling by FcyRIIB1. Thus, a tyrosine mutation that
abrogates the association of PTP1C with FcyRIIB1 leads
to a loss of the ability of Fc-yRIIB1 to abort B-cell anti-
gen receptor signalling [12]. Taken together, these results
suggest a model in which immune complexes, by co-
clustering the B-cell antigen receptor and Fc-yRIIB1,
trigger the tyrosine phosphorylation of FcyRIIB1. This
phosphorylation recruits PTP1C to the B-cell antigen
receptor-FcyRIIB1 complex and activates its phos-
phatase activity, leading to the termination of B-cell anti-
gen receptor signals by dephosphorylating either B-cell
antigen receptor chains or downstream signalling effectors.
Now that PTPlC has been shown to terminate signals,
we will certainly see an intense effort to explore the reg-
ulatory role of protein tyrosine phosphatases in many dif-
ferent systems. Negative regulation by protein tyrosine
phosphatases may well prove to be a common mecha-
nism for switching off signal transduction by receptors
that activate protein tyrosine kinases.
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